How long will my repair last, doctor? Additional data on the durability of mitral valve repair

Stephanie Mick, MD, Kenneth McCurry, MD, Jose Navia, MD, and Marc Gillinov, MD

Preoperative discussions between surgeons and patients before mitral valve surgery often include commentary on what patients should expect in terms of durability following valve repair. Patients are often worried about their “broken” valve and wonder whether the valve might “break” again and lead them back to the operating room. Surgeons are anxious to provide accurate and individualized information to guide patients to clear and appropriate expectations.

In this issue of the Journal, Tatum and colleagues provide data that add to the body of knowledge on this topic. In their single-center series of 446 patients who underwent mitral valve repair, survival was excellent at 95% at 5 years and 94% at 10 years. The overall incidence of reoperation (taking death into consideration as a competing risk) was 5.1% at 5 years and 9.6% at 10 years. Importantly, those patients who underwent posterior leaflet repair experienced a lower incidence of reoperation, 4.3% at 5 years and 5.7% at 10 years.

The overall incidence of progression of mitral regurgitation by 2 or more grades (again with mortality as a competing risk) was 21% at 5 years and 35.8% at 10 years, whereas overall progression to the more clinically relevant moderate-to-severe or severe mitral regurgitation was 7% at 5 years and 26% at 10 years. Echoing the reoperation data, there was a strong trend toward posterior leaflet repair being protective against progression of mitral regurgitation. This finding is consistent with previous reports associating anterior or bileaflet pathologies with increased risk of progression of mitral regurgitation following repair.2,3

Although limited by lack of complete follow-up data (with postoperative echocardiograms unavailable in 25% of the patients) and the authors’ reliance on outside transthoracic echocardiography reports, the present work, along with previous research, provides the cardiac surgeon with an additional measure of confidence in guiding patients’ expectations both preoperatively and postoperatively. If a posterior leaflet repair appears to be likely or has been performed, the surgeon can confidently quote a low risk of reoperation, and if not, he or she may temper his or her prediction.

The excellent results of mitral valve repair should be kept in mind in this era of heightened enthusiasm for percutaneous structural interventions and increasing interest in the application of these new technologies in patients who are candidates for conventional surgery. Although the MitraClip (Abbott Vascular, Abbott Park, Ill) remains the sole percutaneous therapy approved for use in the United States for degenerative mitral valve disease, multiple technologies are currently in development. As such devices come out of the “pipeline” and into active use in trials, surgeons will be called on to recommend for or against consideration of percutaneous measures. It will be of critical importance to keep the kinds of data provided by Tatum and colleagues in mind. Particularly in the case of posterior leaflet pathology, mitral valve repair represents the gold standard for the treatment of degenerative mitral valve disease, and the bar is set high for competing therapies.

References